Myc-Miz1信号通过抑制Cebpα和Cebpδ促进白血病干细胞自我更新
研究探讨Myc-Miz1转录抑制活性在急性髓系白血病(AML)中的作用。缺乏Miz1结合能力的MycV394D突变体致癌功能显著减弱,在MLL-AF9小鼠AML模型中白血病干细胞频率降低、自我更新能力受损,且对化疗更敏感。机制上Myc通过抑制Miz1介导的Cebpα和Cebpδ表达维持白血病干细胞未分化状态。
要点
- Myc-Miz1转录抑制活性对AML发生和白血病干细胞自我更新至关重要
- 表达MycV394D的白血病细胞部分分化、集落形成和致白血病能力下降
- Myc通过抑制Cebpα和Cebpδ表达维持白血病干细胞未分化状态
核心结论
- Myc-Miz1相互作用是白血病干细胞自我更新所必需的,其转录抑制功能在AML发病中起重要作用。
研究设计与样本
- 使用MycV394D突变体(缺乏Miz1结合及转录抑制活性)转导造血干/祖细胞(HSPCs)的小鼠移植实验。
- 采用小鼠MLL-AF9 AML模型,比较表达MycV394D(内源性Myc缺失)与Myc的白血病细胞。
- 通过体外集落形成实验和体内连续移植实验评估白血病干细胞频率和致白血病能力。
主要发现
- 与Myc相比,MycV394D的致癌功能显著受损,受体小鼠AML/骨髓增殖性疾病发生显著延迟。
- 表达MycV394D的AML细胞部分分化,体外集落形成能力和体内致白血病能力均降低。
- MycV394D-AML细胞中白血病干细胞频率降低,连续移植中致白血病能力减弱。
- MycV394D-AML细胞对化疗比Myc-AML细胞更敏感。
- 机制上Myc抑制Miz1介导的Cebpα和Cebpδ表达,维持白血病干细胞未分化状态和自我更新能力。
临床怎么用
- 靶向Myc-Miz1相互作用或其下游Cebpα/Cebpδ通路可能成为清除白血病干细胞的新策略。
- Myc-Miz1转录抑制功能缺陷的白血病细胞对化疗更敏感,提示联合靶向该通路可能增敏化疗。
局限性
- 主要证据来自小鼠MLL-AF9 AML模型和MycV394D突变体,尚未在人类AML样本中验证。
- Myc-Miz1转录抑制活性的具体下游靶基因网络及临床相关性仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
c-Myc (Myc hereafter) is found to be deregulated and/or amplified in most acute myeloid leukemias (AMLs). Almost all AML cells are dependent upon Myc for their proliferation and survival. Thus, Myc has been proposed as a critical anti-AML target. Myc has Max-mediated transactivational and Myc-interacting zinc finger protein 1 (Miz1)-mediated transrepressional activities. The role of Myc-Max-mediated transactivation in the pathogenesis of AML has been well studied; however, the role of Myc-Miz1-mediated transrepression in AML is still somewhat obscure. Myc protein harboring a V394D mutation (MycV394D) is a mutant form of Myc that lacks transrepressional activity due to a defect in its ability to interact with Miz1. We found that, compared with Myc, the oncogenic function of MycV394D is significantly impaired. The AML/myeloproliferative disorder that develops in mice receiving MycV394D-transduced hematopoietic stem/progenitor cells (HSPCs) is significantly delayed compared with mice receiving Myc-transduced HSPCs. Using a murine MLL-AF9 AML model, we found that AML cells expressing MycV394D (intrinsic Myc deleted) are partially differentiated and show reductions in both colony-forming ability in vitro and leukemogenic capacity in vivo. The reduced frequency of leukemia stem cells (LSCs) among MycV394D-AML cells and their reduced leukemogenic capacity during serial transplantation suggest that Myc-Miz1 interaction is required for the self-renewal of LSCs. In addition, we found that MycV394D-AML cells are more sensitive to chemotherapy than are Myc-AML cells. Mechanistically, we found that Myc represses Miz1-mediated expression of CCAAT/enhancer-binding protein α (Cebpα) and Cebpδ, thus playing an important role in the pathogenesis of AML by maintaining the undifferentiated state and self-renewal capacity of LSCs.
引用
- Zhang L, Li J, Xu H, et al. Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ. Blood. 2020. PMID: 32040550. doi:10.1182/blood.2019001863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。